How does 8YY's PS Ratio compare to its peers?

8YY is expensive based on its Price-To-Sales Ratio (13.2x) compared to the peer average (1.6x).

How does 8YY's PS Ratio compare vs other companies in the Asian Medical Equipment Industry?

8YY is expensive based on its Price-To-Sales Ratio (13.2x) compared to the Asian Medical Equipment industry average (3.3x).

What is 8YY's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

Insufficient data to calculate 8YY's Price-To-Sales Fair Ratio for valuation analysis.

What is the Fair Price of 8YY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Insufficient data to calculate 8YY's fair value for valuation analysis.

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Insufficient data to show price forecast.

Biolidics (Catalist:8YY) - Stock Price, News & Analysis

8YY Stock Overview

A precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions. More details

8YY fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Earnings have grown 0.4% per year over the past 5 years

Risk Analysis

Shareholders have been substantially diluted in the past year

Negative shareholders equity

Makes less than USD$1m in revenue (SGD1M)

Highly volatile share price over the past 3 months compared to the SG market

+ 1 more risk

Biolidics Limited Competitors

Vicplas International

SGX:569

S$45.5m

Quantum Healthcare

Catalist:V8Y

S$16.0m

AJJ Medtech Holdings

Catalist:584

S$7.5m

Niks Professional

Catalist:NPL

S$17.9m

Price History & Performance

Summary of all time highs, changes and price drops for Biolidics
Historical stock prices
Current Share Price	S$0.01
52 Week High	S$0.018
52 Week Low	S$0.008
Beta	0.64
11 Month Change	25.00%
3 Month Change	0%
1 Year Change	-23.08%
33 Year Change	-94.25%
5 Year Change	-96.23%
Change since IPO	-95.74%

Recent updates

Shareholder Returns

	8YY	SG Medical Equipment	SG Market
7D	0%	-1.0%	0.5%
1Y	-23.1%	1.0%	14.1%

Return vs Industry: 8YY underperformed the SG Medical Equipment industry which returned 1% over the past year.

Return vs Market: 8YY underperformed the SG Market which returned 14.1% over the past year.

Price Volatility

Is 8YY's price volatile compared to industry and market?
8YY volatility
8YY Average Weekly Movement	18.2%
Medical Equipment Industry Average Movement	6.8%
Market Average Movement	4.6%
10% most volatile stocks in SG Market	14.4%
10% least volatile stocks in SG Market	2.1%

Stable Share Price: 8YY's share price has been volatile over the past 3 months compared to the SG market.

Volatility Over Time: 8YY's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of SG stocks.

About the Company

Founded	Employees	CEO	Website
2009	15	n/a	www.biolidics.com

Biolidics Limited, a precision medicine medical technology company, focuses on developing a portfolio of diagnostic solutions. The company operates through Cancer, Infectious Diseases, and Laboratory Services segments. It provides Covid-19 PCR testing kits.

Biolidics Limited Fundamentals Summary

How do Biolidics's earnings and revenue compare to its market cap?
8YY fundamental statistics
Market cap	S$16.91m
Earnings (TTM)	-S$2.95m
Revenue (TTM)	S$1.28m

13.2x

P/S Ratio

-5.7x

P/E Ratio

Is 8YY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8YY income statement (TTM)
Revenue	S$1.28m
Cost of Revenue	S$703.00k
Gross Profit	S$579.00k
Other Expenses	S$3.53m
Earnings	-S$2.95m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0017
Gross Margin	45.16%
Net Profit Margin	-230.03%
Debt/Equity Ratio	-84.1%

How did 8YY perform over the long term?

See historical performance and comparison

8YY Stock Overview

Rewards

Risk Analysis

Biolidics Limited Competitors

SGX:569

S$45.5m

Catalist:V8Y

S$16.0m

Catalist:584

S$7.5m

Catalist:NPL

S$17.9m

Price History & Performance

Recent News & Updates

Third quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 3Q 2023)

Biolidics Limited (Catalist:8YY) completed the acquisition of Shenzhen Xiaozhao Network Technology Co., Ltd from Dreamsgame Inc.

New major risk - Shareholder dilution

Second quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 2Q 2023)

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Lead Independent Director and Member of the AC and RR

Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller

Recent updates

Third quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 3Q 2023)

Biolidics Limited (Catalist:8YY) completed the acquisition of Shenzhen Xiaozhao Network Technology Co., Ltd from Dreamsgame Inc.

New major risk - Shareholder dilution

Second quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 2Q 2023)

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Lead Independent Director and Member of the AC and RR

Biolidics Limited Announces the Resignation of Siu Yeung Sau as Financial Controller

First quarter 2024 earnings released: S$0.001 loss per share (vs S$0.001 loss in 1Q 2023)

New major risk - Revenue size

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited, Annual General Meeting, Apr 29, 2024

Biolidics Limited Announces the Redesignation of Zhu Hua from Non-Executive Non-Independent Director to Executive Director

New minor risk - Insider selling

Full year 2023 earnings released: S$0.004 loss per share (vs S$0.033 loss in FY 2022)

Biolidics Limited has completed a Follow-on Equity Offering in the amount of SGD 1.0043 million.

Biolidics Limited has completed a Follow-on Equity Offering in the amount of SGD 1.0043 million.

High number of new and inexperienced directors

Biolidics Limited Appoints Zhu Hua as A Non-Executive Non-Independent Director

Biolidics Limited Announces Board Changes

Biolidics Limited has filed a Follow-on Equity Offering in the amount of SGD 1.17215 million.

Third quarter 2023 earnings released: S$0.001 loss per share (vs S$0.003 loss in 3Q 2022)

New major risk - Share price stability

Biolidics Limited Announces Resignation of Gavin Mark Mcintyre as Independent Director and Non-Executive Independent Chairman, Chairman of the Ac and Member of the NC and the RC

Second quarter 2023 earnings released: S$0.001 loss per share (vs S$0.004 loss in 2Q 2022)

First quarter 2023 earnings released: S$0.001 loss per share (vs S$0.004 loss in 1Q 2022)

Full year 2022 earnings released: S$0.033 loss per share (vs S$0.023 loss in FY 2021)

Biolidics Limited Provides Group Earnings Guidance for the Financial Year Ended 31 December 2022

High number of new and inexperienced directors

Third quarter 2022 earnings released: S$0.003 loss per share (vs S$0.006 loss in 3Q 2021)

High number of new and inexperienced directors

Biolidics Limited Announces Management Changes

First half 2022 earnings released

Biolidics Limited Announces Company Secretary Changes

Biolidics Limited Ordinary Shares Japan to Be Deleted from OTC Equity

Biolidics Limited Announces Company Secretary Changes, Effective from 24 June 2022

Biolidics Limited Announces Resignation of Leong Man Chun as Chief Scientific Officer

Biolidics Limited Appoints Siu Yeung Sau as Financial Controller

Full year 2021 earnings released: S$0.023 loss per share (vs S$0.018 loss in FY 2020)

Biolidics Limited, Annual General Meeting, Apr 28, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Biolidics Limited Announces Changes to the Composition of the Board of Directors and Board Committees of the Company

High number of new directors

Biolidics Limited Provides Update on Development of the ClearEpi SARS-CoV-2 Neutralising Antibody Rapid Test Kit and Receipt of CE Marking

Director Chee Keong Kong sitting on 3 company boards

Chief Operating Officer Qingyin Wang has left the company

Independent Director has left the company

Independent Director has left the company

Full year 2020 earnings released: S$0.018 loss per share (vs S$0.02 loss in FY 2019)

Biolidics Limited Provides Update on ClearEpi SARS-CoV-2 Antigen Rapid Test Kit

New 90-day low: S$0.28

Full year 2020 earnings released

Biolidics Limited Announces Distribution Agreement with Joysbio (Tianjin) Biotechnology Co, Ltd

New 90-day low: S$0.28

New 90-day low - S$0.28

Earnings released

Shareholder Returns

Price Volatility

About the Company

Biolidics Limited Fundamentals Summary

13.2x